EGFR and neoplasm: Of note, patients with low levels of EGFR‐activating mutation allele fractions had reduced tumour burden (median 17 mm) by RECIST measurements, as compared to those with intermediate (median 42 mm) and high (median 80 mm) levels of EGFR‐activating mutation (Appendix Table S4).